Skip to content

Corbus Pharmaceuticals Holdings, Inc.: 10-K filed 2016-03-28

What Corbus Pharmaceuticals Holdings, Inc. reported in its annual report filed 2016-03-28 (fiscal FY 2015): 28 published measures, 56 facts as tagged in accession 0001564590-16-015403.

This filing

Form
10-K (annual report)
Filed
2016-03-28
Fiscal period
fiscal FY 2015
Accession
0001564590-16-015403 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All Corbus Pharmaceuticals Holdings, Inc. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2015-12-3112,875,303USD
At 2014-12-316,600,773USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

PeriodValueUnitDays
At 2015-12-313,890,293USD
At 2014-12-31738,040USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2015-12-318,985,010USD
At 2014-12-315,862,733USD
At 2013-12-31-1,783,198USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

PeriodValueUnitDays
At 2015-12-3112,338,275USD
At 2014-12-316,262,445USD
At 2013-12-31303,020USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2015-01-01 to 2015-12-31-8,850,739USD365
2014-01-01 to 2014-12-31-2,540,485USD365

Capital expenditure payments

Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.

PeriodValueUnitDays
2015-01-01 to 2015-12-31114,037USD365
2014-01-01 to 2014-12-3164,448USD365

Revenue

Revenue under this specific accounting concept. A missing value is not zero; filers can use other revenue concepts.

PeriodValueUnitDays
2015-01-01 to 2015-12-31648,382USD365

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2015-12-31-13,277,814USD
At 2014-12-31-4,427,075USD

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

PeriodValueUnitDays
At 2015-12-31124,138USD
At 2014-12-3154,044USD

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

PeriodValueUnitDays
2015-01-01 to 2015-12-311,153,302USD365
2014-01-01 to 2014-12-31193,120USD365

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2015-01-01 to 2015-12-31-8,853,693USD365
2014-01-01 to 2014-12-31-2,647,173USD365

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2015-12-3112,714,790USD
At 2014-12-316,533,001USD

Interest expense

Borrowing costs recognized as interest expense. This is distinct from cash interest paid and may not include every capitalized borrowing cost.

PeriodValueUnitDays
2015-01-01 to 2015-12-312,440USD365
2014-01-01 to 2014-12-3124,021USD365

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2015-12-313,630,033USD
At 2014-12-31738,040USD

Current accounts payable

Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.

PeriodValueUnitDays
At 2015-12-311,314,377USD
At 2014-12-31344,160USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

PeriodValueUnitDays
2015-01-01 to 2015-12-319,502,075USD365
2014-01-01 to 2014-12-312,647,173USD365

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

PeriodValueUnitDays
2015-01-01 to 2015-12-315,888,659USD365
2014-01-01 to 2014-12-311,255,535USD365

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2015-12-3137,605,134shares
At 2014-12-3125,938,332shares

Accumulated depreciation on property, plant and equipment

Cumulative depreciation, depletion and amortization recorded against property, plant and equipment. It measures cost allocation to date, not physical wear or market value.

PeriodValueUnitDays
At 2015-12-3154,348USD
At 2014-12-3110,405USD

Accrued current liabilities

Current obligations accrued for goods and services received but not yet invoiced or paid. This is one component of current liabilities, not all short-term obligations.

PeriodValueUnitDays
At 2015-12-31562,279USD
At 2014-12-31249,491USD

Net deferred tax assets

Deferred tax assets after the valuation allowance. Realization depends on future taxable income, so the balance is not a receivable from tax authorities.

PeriodValueUnitDays
At 2015-12-310USD
At 2014-12-310USD

Net income available to common stockholders

Net income after preferred dividends and similar adjustments, the numerator for basic earnings per share. It can be lower than reported net income.

PeriodValueUnitDays
2015-01-01 to 2015-12-31-8,850,739USD365
2014-01-01 to 2014-12-31-2,540,485USD365

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

PeriodValueUnitDays
2015-01-01 to 2015-12-313,613,416USD365
2014-01-01 to 2014-12-311,391,638USD365

Depreciation expense

Depreciation recognized for the period under this concept. It is a noncash allocation of asset cost and may exclude amortization and depletion reported elsewhere.

PeriodValueUnitDays
2015-01-01 to 2015-12-3143,943USD365
2014-01-01 to 2014-12-3110,405USD365

Nonoperating income or expense

Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.

PeriodValueUnitDays
2015-01-01 to 2015-12-312,954USD365
2014-01-01 to 2014-12-31106,688USD365

Current income tax expense or benefit

Income tax expense or benefit for the period that is currently payable or refundable. It differs from cash taxes paid and from total tax expense.

PeriodValueUnitDays
2015-01-01 to 2015-12-310USD365

Proceeds from issuing common stock

Cash received from issuing common stock during the period. It is gross of costs only where the filer reports it so, and it does not include noncash issuances.

PeriodValueUnitDays
2015-01-01 to 2015-12-3111,328,929USD365
2014-01-01 to 2014-12-3110,305,161USD365

Change in accounts payable

The cash flow adjustment for the change in payables during the period. A positive value under this concept means payables grew and added to operating cash flow.

PeriodValueUnitDays
2015-01-01 to 2015-12-31972,194USD365
2014-01-01 to 2014-12-31170,239USD365

Inspect the source

Entity
Corbus Pharmaceuticals Holdings, Inc. / CIK 0001595097
Captured
2026-09-20T09:24:35.285Z
SEC response SHA-256
946cd75b294f9564550986f5a835381ea0b20b9b7c1140d70659a5c384e7d54a

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001595097.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))